金石亚药：全资子公司获得硫酸氨基葡萄糖胶囊药品注册证书

Core Viewpoint - The company has received approval for its glucosamine sulfate capsules, which are indicated for osteoarthritis, marking a significant milestone in its product development and market entry strategy [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Zhejiang Yake Pharmaceutical Co., Ltd., has been granted a drug registration certificate for glucosamine sulfate capsules by the National Medical Products Administration (NMPA) [1] - The approval is considered equivalent to passing the consistency evaluation for generic drugs, enhancing the company's competitive position in the market [1] Group 2: Product Information - Glucosamine sulfate capsules are classified as non-prescription analgesic medications, specifically indicated for primary and secondary osteoarthritis [1] - The application for this product was submitted to the NMPA in May 2024 and has since been accepted [1] Group 3: Market Context - As of the announcement date, over twenty manufacturers, including the company, have either passed or are deemed to have passed the consistency evaluation for glucosamine sulfate capsules [1]